Elorac, Inc. Announces FDA Fast Track Designation for Novel Topical Treatment for Pruritus in Cutaneous T-cell Lymphoma (CTCL)
4/12/2013 9:28:02 AM
More...
|
Elorac, Inc. Announces Orphan Designation in Europe for Novel Topical Treatment for Cutaneous T-Cell Lymphoma (CTCL)
11/16/2012 9:02:20 AM
More...
|
Elorac, Inc. Gives Back to Young Campers with Chronic Skin Conditions Through a Generous Donation to Camp Discovery
12/20/2011 8:59:50 AM
More...
|
Elorac, Inc. Promotes Christopher Gabanski as Chief Commercial Officer
7/22/2011 6:25:01 AM
More...
|
Elorac, Inc. Announces Orphan Drug Designation for Novel Topical Treatment for Pruritus in Cutaneous T-cell Lymphoma (CTCL)
11/30/2010 9:11:54 AM
More...
|
Elorac, Inc. Announces Clinical Results of Carbamide Peroxide Studies for the Treatment of Acne
11/19/2010 10:41:53 AM
More...
|
Elorac, Inc. to Present at Lazard Capital Markets 7th Annual Healthcare Conference
11/10/2010 11:59:00 AM
More...
|
Elorac, Inc. Announces Acquisition of All World-wide Rights to Cidoxepin
10/19/2010 9:14:44 AM
More...
|
Elorac, Inc. Launches the Avenue to Access(TM) Free Psoriasis Medication Program
8/4/2010 10:41:04 AM
More...
|
Elorac, Inc. Announces Launch of Novel, Steroid-free, Prescription Cream for Psoriasis
8/27/2009 11:09:38 AM
More...
|